Marinus Pharmaceuticals, Inc. updated revenue guidance for the fiscal year 2023. For the year, the Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.375 USD | +3.38% | -7.09% | -87.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.35% | 73.06M | |
+29.71% | 684B | |
+29.28% | 568B | |
-4.21% | 361B | |
+18.61% | 329B | |
+4.52% | 284B | |
+15.96% | 240B | |
+9.26% | 208B | |
-7.03% | 200B | |
+7.49% | 166B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023